Welcome to
Sanofi in Canada
Toggle navigation
About Us
Science & Innovation
Products and Resources
Patient Support
Our Responsibility
Careers
Media
Toggle navigation
News Releases
Subscribe
Media Contacts
Social Media
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Subscribe
Year
All Years
2023
2022
2021
2020
2019
2018
2017
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
May 4, 2023
DUPIXENT® (dupilumab injection) is now approved in Canada for the treatment of adult and adolescent patients (12+) with Eosinophilic Esophagitis
May 1, 2023
Libtayo® (cemiplimab) in Combination with Chemotherapy now approved in Canada for the First-line Treatment of Advanced Non-small Cell Lung Cancer
May 1, 2023
Sanofi Canada and Diabetes Care Community announce a collaboration to support the emotional well-being journey of Canadians living with diabetes
Apr 24, 2023
Health Canada approves BEYFORTUS™ (nirsevimab) for the prevention of RSV disease in infants
Apr 20, 2023
DUPIXENT® (dupilumab injection) now approved in Canada for children as young as six months old with severe atopic dermatitis
Show
5
10
25
50
100
per page
«
1
2
3
4
5
6
7
8
9
…
17
»
